Full Press Release Details
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME.
IMTX
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Key Takeaway: Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
Price reaction · baseline $8.17 (2024-11-15 close) · clean, no other IMTX news in the window
day 0 close · peak
-4.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+20%
120-day peak, hindsight
Typical move
3.9%
average across 7 past catalysts
Lead asset
IMA401
Phase 1 · Refractory Cancer